Trial Profile
TRI-stent Adjudication Study - Low risk of Restenosis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Anti-CD34 monoclonal antibody (Primary) ; Paclitaxel; Sirolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms TRIAS-LR
- 01 Sep 2020 Primary endpoint (Target lesion failure within one year) has not been met as per results presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 01 Sep 2020 Final 5 year results of the TRIAS LR presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 21 Mar 2014 According to ISRCTN: Current Controlled Trials, status changed from recruiting to discontinued.